Vaxart delisted from Nasdaq, begins trading on OTCQX after bid price failure

Vaxart, Inc.

Nasdaq delisted VXRT for non-compliance with minimum bid price requirement (Rule 5550(a)(2)).
Trading suspended on Nasdaq July 8, 2025; stock began same-day trading on OTCQX Best Market under same ticker.
Vaxart appealed the delisting on July 3, 2025; shares remain suspended on Nasdaq pending hearing panel decision.
CEO Steven Lo says focus remains on advancing oral pill vaccine pipeline while considering listing options.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.